4 research outputs found
Total Synthesis and Comparative Evaluation of Luzopeptin A−C and Quinoxapeptin A−C
Full details of the total syntheses of luzopeptin A−C and quinoxapeptin A−C, C2-symmetric cyclic
depsidecapeptides bearing two pendant heterocyclic chromophores, are disclosed and serve to establish the
quinoxapeptin relative and absolute configuration. Key elements of the approach include the late-stage
introduction of the chromophore and penultimate l-Htp acylation permitting the divergent synthesis of the
luzopeptins, quinoxapeptins, and structural analogues from a common advanced intermediate. Symmetrical
pentadepsipeptide coupling and macrocyclization of the 32-membered ring conducted at the single secondary
amide site provided the common cyclic decadepsipeptide. The convergent preparation of the required
pentadepsipeptide with installation of the labile ester in the final coupling was achieved under surprisingly
effective racemization-free conditions. The quinoxapeptins were shown to bind to DNA by high-affinity
bisintercalation analogous to sandramycin and the luzopeptins. Significant similarities in the DNA binding of
sandramycin and luzopeptin A were observed, and these compounds proved distinguishable from the
quinoxapeptins, indicating that the structural alterations in the chromophore impact the affinity and selectivity
more than the changes in the decadepsipeptide. The luzopeptins proved to be more potent cytotoxic agents
than the corresponding quinoxapeptin, but the quinoxapeptins proved to be more potent inhibitors of HIV-1
reverse transcriptase. In addition, a well-defined potency order was observed in the cytotoxic assays (A > B
> C) in which the distinctions were extraordinarily large, with the removal of each l-Htp acyl substituent
resulting in a 100−1000-fold reduction in potency. An equally well-defined but reverse potency order was
observed in HIV-1 reverse transcriptase inhibition (C > B > A). Thus, the non-naturally occurring synthetic
precursor 6 (quinoxapeptin C) was found to exhibit the most potent HIV-1 reverse transcriptase inhibition in
the series and to lack a dose-limiting in vitro cytotoxic activity, making it the most attractive member of the
series examined
Novel Antibacterial Macrolides: Synthesis of 15-Membered Diolides
Novel 15-membered macrolides possessing the dilactone skeleton, diolides 13a and 13b, have been
synthesized in our research program aimed at finding new antibacterial macrolides. Key strategic
elements of the approach include the ring-expanding reaction of 13-membered dilactones, prepared
from erythromycin A (Ery-A), to 15-membered dilactones via intramolecular translactonization.
The absolute configuration at the regenerated C-8 position of the new diolides was determined by
chemical transformation, leading to the corresponding lactam analogues, whose stereochemistry
is known in the literature. For further confirmation, X-ray analysis was performed. The X-ray
structure determination of 13a revealed a backbone conformation similar to that of Ery-A. Novel
15-membered diolide 13a and the 11,12-diol 18 exhibited antibacterial activities comparable to
that of Ery-A
Novel Antibacterial Macrolides: Synthesis of 15-Membered Diolides
Novel 15-membered macrolides possessing the dilactone skeleton, diolides 13a and 13b, have been
synthesized in our research program aimed at finding new antibacterial macrolides. Key strategic
elements of the approach include the ring-expanding reaction of 13-membered dilactones, prepared
from erythromycin A (Ery-A), to 15-membered dilactones via intramolecular translactonization.
The absolute configuration at the regenerated C-8 position of the new diolides was determined by
chemical transformation, leading to the corresponding lactam analogues, whose stereochemistry
is known in the literature. For further confirmation, X-ray analysis was performed. The X-ray
structure determination of 13a revealed a backbone conformation similar to that of Ery-A. Novel
15-membered diolide 13a and the 11,12-diol 18 exhibited antibacterial activities comparable to
that of Ery-A
